Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,425,504
  • Shares Outstanding, K 1,241,421
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.37
  • Price/Sales 6.18
  • Price/Cash Flow 14.01
  • Price/Book 8.04

Options Overview Details

View History
  • Implied Volatility 29.17% (+0.65%)
  • Historical Volatility 30.09%
  • IV Percentile 43%
  • IV Rank 27.10%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 2) 3.32 (2.26%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 385
  • Volume Avg (30-Day) 7,251
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 160,397
  • Open Int (30-Day) 162,708
  • Expected Range 143.85 to 150.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.86
  • Number of Estimates 9
  • High Estimate 1.97
  • Low Estimate 1.73
  • Prior Year 1.81
  • Growth Rate Est. (year over year) +2.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
142.77 +3.06%
on 03/06/26
156.95 -6.25%
on 02/13/26
-8.66 (-5.56%)
since 02/11/26
3-Month
116.88 +25.89%
on 01/05/26
157.29 -6.45%
on 02/11/26
+23.93 (+19.42%)
since 12/11/25
52-Week
93.37 +57.59%
on 04/25/25
157.29 -6.45%
on 02/11/26
+32.71 (+28.59%)
since 03/11/25

Most Recent Stories

More News
3 Blue-Chip Stocks Built for a Rotating Market

Investors are rotating out of overvalued mega-cap tech as the broader economy heats up; these three blue-chip stocks are attracting attention

DUK : 129.67 (-0.02%)
GILD : 147.39 (-0.79%)
HSY : 216.10 (-1.32%)
These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

V : 312.38 (-0.65%)
GILD : 147.39 (-0.79%)
ABBV : 228.66 (+0.73%)
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

– Grants to Strengthen Prevention Models and Local Systems of Care Nationwide –

GILD : 147.39 (-0.79%)
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

ACLX : 114.37 (-0.02%)
XLV : 152.37 (-0.51%)
MRK : 116.04 (-0.90%)
GILD : 147.39 (-0.79%)
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier to Resistance with Lenacapavir, a First-in-Class...

GILD : 147.39 (-0.79%)
Is Amgen Stock Outperforming the Dow?

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

$DOWI : 47,297.12 (-0.86%)
GILD : 147.39 (-0.79%)
AMGN : 377.67 (+0.60%)
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

NFLX : 95.91 (-1.06%)
VRTX : 493.26 (-1.18%)
GILD : 147.39 (-0.79%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 114.37 (-0.02%)
GILD : 147.39 (-0.79%)
Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday,...

GILD : 147.39 (-0.79%)
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

– Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma – – ...

ACLX : 114.37 (-0.02%)
GILD : 147.39 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 152.23
2nd Resistance Point 150.80
1st Resistance Point 149.68
Last Price 147.39
1st Support Level 147.14
2nd Support Level 145.71
3rd Support Level 144.59

See More

52-Week High 157.29
Last Price 147.39
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar